Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Stadler

Showing results (61-70 of 138) with videos related to

Pageof 14
Sort By:
Oral Oncology|October 7, 2019
Lymph node yield, depth of invasion, and survival in node-negative oral cavity cancerJoseph Zenga, Vasu Divi, Michael Stadler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99Jakob R Passweg, Aristoteles A N Giagounidis, Mathew Simcock, et al.
Annals of Hematology|July 25, 2020
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-upRabia Shahswar, Gernot Beutel, Razif Gabdoulline, et al.
Rheumatology Advances in Practice|January 5, 2026
Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDsMichael Stadler, Shae Bindra, Annie Cheung, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 28, 2017
Possible Impact of Cytomegalovirus-Specific CD8<sup>+</sup> T Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic Stem Cell TransplantationJustyna Ogonek, Pavankumar Varanasi, Susanne Luther, et al.
Leukemia Research|October 9, 2017
Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotypeLaura Hörster, Richard F Schlenk, Michael Stadler, et al.
Transfusion|November 26, 2009
Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at riskDaphne Dahl, Andreas Hahn, Christian Koenecke, et al.
Haematologica|March 16, 2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Cancer Chemotherapy and Pharmacology|November 19, 2015
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70Taofeek Kunle Owonikoko, Arif Hussain, Walter Michael Stadler, et al.
Scientific Reports|April 20, 2021
Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantationMartin W Hümmert, Michael Stadler, Lothar Hambach, et al.
Pageof 14

Showing results (61-70 of 138) with videos related to

Sort By:
Pageof 14
Oral Oncology|October 7, 2019
Lymph node yield, depth of invasion, and survival in node-negative oral cavity cancerJoseph Zenga, Vasu Divi, Michael Stadler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99Jakob R Passweg, Aristoteles A N Giagounidis, Mathew Simcock, et al.
Annals of Hematology|July 25, 2020
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-upRabia Shahswar, Gernot Beutel, Razif Gabdoulline, et al.
Rheumatology Advances in Practice|January 5, 2026
Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDsMichael Stadler, Shae Bindra, Annie Cheung, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 28, 2017
Possible Impact of Cytomegalovirus-Specific CD8<sup>+</sup> T Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic Stem Cell TransplantationJustyna Ogonek, Pavankumar Varanasi, Susanne Luther, et al.
Leukemia Research|October 9, 2017
Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotypeLaura Hörster, Richard F Schlenk, Michael Stadler, et al.
Transfusion|November 26, 2009
Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at riskDaphne Dahl, Andreas Hahn, Christian Koenecke, et al.
Haematologica|March 16, 2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Cancer Chemotherapy and Pharmacology|November 19, 2015
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70Taofeek Kunle Owonikoko, Arif Hussain, Walter Michael Stadler, et al.
Scientific Reports|April 20, 2021
Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantationMartin W Hümmert, Michael Stadler, Lothar Hambach, et al.
Pageof 14